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TOPOGRAPHY STUDY OF FIXA: GENERATION OF A LIPID
ANCHORED MOLECULAR RULER WITH ATTACHED INHIBITOR
Abstract
Blood coagulation, an important hemostatic property, is directed through
activation of proteolytic enzymes known as serine proteases to generate a fibrin
plug. Using multiple proteases allows for localized and precise regulation of
blood coagulation within the circulatory system. Factor IX, a serine protease, is a
key activator in the coagulation cascade by activating Factor X. For activation of
FX to occur, FIXa must be in proper conformation on the platelet surface with
cofactor FVIIIa to increase enzymatic abilities of FIXa a billion-fold. Current
research looks at structure and function of FIXa yet neglects structural plasticity
on the membrane, with function of FIX clearly being related to conformation on
the platelet. The role of this investigation was to study the optimal reactive
topography of FIXa by generating AMRI, Adjustable height Molecular Ruler with
attached Inhibitor. AMRI composed of three primary regions contains an Anchor
region, Linker region, and Inhibitor. AMRI was generated using the protein
anchoring sequence LAGC to fixate to a lipid surface. A height adjustable linker
area was then required between the anchor and inhibitor regions of AMRI to
ensure proper vertical height of inhibitor. The linker sequence EAAAK forms a
rigid structure with a vertical height of 7.5A above the membrane surface, thus
we repeated this sequence to achieve a specific desired height. Completing the

ii

protein’s linker region is a flexible linker at end of the rigid set. That flexible linker
ensures the inhibitor will fit in FIXa active site. Finishing the AMRI complex is a
PN2-KPI inhibitor, which has been demonstrated to fit and inhibit the catalytic site
of FIXa. Therefore, AMRI should allow for determination of optimal reactive
height of the FIXa active site without affecting structural conformation. Through
the generation of AMRI, a greater insight into blood coagulation will be gained,
along with potential for site specific anticoagulant clinical applications.
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1 Background and Significance
1.1 Hemostasis

Humans are dependent upon the circulation of blood through a pressurized vascular
network to sustain life. Continuous blood flow is vital for the transport of nutrients,
hormones, and waste to allow proper cellular function. The body includes five major
vessel types christened arteries, arterioles, capillaries, venules, and veins. The arteries
and veins contain three different layers termed the tunica intima, tunica media, and
tunica adventitia; constructing the inner, middle, and outer layers, respectively. The
arterioles and venules contain two layers, tunica intima, and tunica media. The
capillaries contain only one layer, the tunica intima. The tunica intima is composed of a
single layer of endothelial cells found in all blood vessels. The other two layers of the
blood vessels are comprised of an extracellular matrix composed of collagens, elastins,
fibrils, and proteoglycans, which provide structure and regulation to blood flow(1, 2).
Hemostasis is the balance of clotting at the site of injury, fibrinolysis as part of
healing and preventing the random clotting to allow flow of blood throughout its system.
The hemostatic system has the responsibility of maintaining integrity of the closed
vascular system. Vascular integrity can be affected by a multitude of things including, a
needle used to draw someone’s blood, rupture of an atherosclerotic plaque, or a deep
laceration during a motor vehicle accident. It is possible that one of these events or
others could affect an individual at any given time, significantly affecting blood flow.
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Failure of vascular integrity resulting in diminished hemostasis will lead to various clinical
pathologies and in extreme circumstances, tissue, and cellular death(3).

1.2 Platelet Activation and Coagulation Cascade

The process of blood changing from a flowing liquid to forming a solid clot is
coagulation. The ultimate goal of coagulation is to achieve hemostasis, by pinpointing
and obstructing the loss of blood at the site of vascular injury. This happens with the
activation and adhesion of platelets providing a surface for clotting enzymes to undergo
a series of reactions forming a clot. These series of enzymatic reactions in conjunction
with platelets can seal off the area of vascular damage by generation of a non-soluble
plasma protein, fibrin(4-6) .
Platelets are found in significant numbers within the blood. In intact blood circulation,
platelets are smooth, discoid in shape, and contain an internal canalicular system.
Additionally, platelets contain granules containing von Willebrand Factor (vWF), plateletactivating factor, and other platelet activating materials(7, 8) .
Activation of platelets is initiated by a rupture in the vessel endothelial lining,
exposing von Willebrand Factor (vWF) and extracellular matrix proteins, such as
collagen, to the blood. This contact between surface receptors on the platelet with these
proteins causes the conformational changes in platelets by extending their pseudopodia
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contained within the canalicular system (8). Translocation of the pseudopodia exposes
the anionic phospholipid layer on their outer surface for attachment of other platelets,
vWF, and other proteins(8-10) .
The mechanism behind the translocation is caused by a platelet membrane receptor,
GPIa, which induces the platelet conformational change (see Figure 1). This change
exposes a second platelet membrane receptor GPIb and in the presence of vWF,
induces greater conformational change. This greater change exposes the GPIIb/GPIII
receptor proteins, allowing for binding of more collagen and vWF(8).
Once platelets are activated, these platelets begin to adhere to one another, in a
process called platelet adhesion. Just as the activation cause the extension of the
pseudopodia and adhesion, it causes the granules to be released from the canalicular
system as well. By releasing the granules, this creates more soluble vWF to activate
more platelets (8) .
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Now with activated platelets, this self-sealing system employs the combination of the
tissue factor pathway and the
contact activation pathway;
termed extrinsic and intrinsic
pathways, respectively. These
pathways are a series of
sequential reactions, in which
Figure
1. Platelet
Adhesion
Steps.
GpIa binds the exposed
Figure
1. Plate
Adhesion
Steps
subendothelial collagen (Step 1) and allows GpIb to bind vWF

the inactive enzyme precursors

(Step 2). This binding with vWF exposes the (Step 3) GpIIb-

(zymogens) of a serine protease

GpIIIa complex. This image was adapted from: Lieberman M,
Marks AD. Marks' basic medical biochemistry

activates to become an activated
serine protease. The

coagulation cascade zymogens are called Factors and identified by Roman numerals
(see Table 1 for a list). Once the Factor has been activated its name indicates so by
following the name with the letter “a”; i.e. Factor IX (FIX) activated is Factor IXa (FIXa).
That serine protease plants on the phospholipid surface provided by the platelet, thus
catalyzing the next reaction in the cascade by cleaving the downstream substrate. The
intrinsic and extrinsic cascades work in tandem having the goal of activating Factor X
(FX), prothrombin (FII), and cleaving fibrinogen (FI) (11-15) .
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Table 1 Blood Coagulation Proteins.
Blood Coagulation Proteins with Common Name, Descriptive Name, and Function. An activated form
has an “a” added to the common name. An * indicated the proteins that are Vitamin K dependent.

Common Name

Alternative
Descriptive Name

Function/Active Form

FI

Fibrinogen

Fibrin

FII*

Prothrombin

Serine protease

FIII

Tissue Factor(TF)

Receptor, Cofactor, and Initiator

FIV

Ca2+

Cofactor

FV

Proaccelerin, labile
factor

Cofactor

FVII*

Proconvertin

Serine protease

FVIII

Antihemophilia factor
A

Cofactor for FIX activation

FIX*

Antihemophilia factor
B, Christmas factor

Serine protease

FX*

Stuart-Prower factor

Serine protease

FXI

Plasma
thromboplastin
antecedent

Serine protease

FXII

Hageman Factor

Serine Protease

FXIII

Fibrin-stabilizing
factor

Ca2+-dependent transglutaminase

Thrombomodulin

Thrombin Cofactor in Protein C
Activation, Endothelial Cell Receptor

Protein C*

Serine Protease, Activated by
Thrombomodulin-bound thrombin

Protein S*
Antithrombin III

Cofactor for activated Protein C
ATIII

Protease Inhibitor

6
The Extrinsic pathway, as seen in figure 2, is composed of Tissue Factor (TF) and
Factor VII (FVII) to activate FX (16) . TF is expressed on subendothelial tissues and
fibroblast cells outside of the vasculature. This is vital for pinpoint identification of a
vascular break and formation of the TF-FVIIa complex (3, 17, 18) . The TF-FVIIa
complex then activates FX and FIX (19, 20).
The Intrinsic pathway is composed Coagulation Factors IX, VIII, and XI (see Figure
2). Again, the goal is to activate Factor X and ultimately generate a thrombin burst. The
pathway starts with the activation of FXII that converts FXI to FXIa. FXIa then cleaves
FIX, activating to create FIXa. Then FIXa interacts with FVIIIa to form the tenase
complex, whose role is to activate FX into FXa (12).

Extrinsic and
intrinsic pathway
activation results in
the activation of the
common pathway for
a favorable thrombin
generation state (see
Figure 2. Blood Coagulation Cascade showing the overall goal of activation of FX
to Xa to for the prothrombin complex to form a hard fibrin clot. Not shown are the
necessary cofactors that are required for full procoagulant activity. Adapted from:
Lieberman M, Marks AD. Marks' basic medical biochemistry: A clinical approach.
4th ed. Lippincott Williams & Wilkins; 2012.

Figure 2). The
central objective of
the common pathway
is to activate FX,
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thrombin, and fibrin, inducing clotting. This central objective is best achieved when
coagulation is viewed as the Cell-Based Model for Coagulation (CBMC) (21). The
CBMC model accounts for the fact that both pathways are necessary to form a fibrin clot
and that if one is deficient this leads to clinical issues such as hemophilia or
spontaneous clot formation. CBMC is a four-step process for coagulation, composed of
Initiation, Amplification, Propagation, and Termination (21).
Initiation occurs when trauma leads to the exposure of TF, extracellular collagen, and
von Willebrand Factor (vWF) (13, 17, 22). These indicators allow for injury site detection
with pinpoint precision and initiate a response. Platelets, activated by vWF and
extracellular collagen, extend their pseudopodia. The activation of platelets and
exposure of the TF bearing tissue to circulating blood is important for providing an
anionic phospholipid layer for the coagulation factors to sit on (12, 23).
Simultaneous to the platelet activation is the formation of a complex between
Coagulation Factor VII (FVII) and Tissue Factor (TF) (23). FVII activation is brought
about by auto-activation or activation by trace amounts of FXa (24). Formation of this
complex activates a small amount of FIX and FX via proteolytic cleavage, producing
FIXa and FXa (10, 25, 26). This small amount of FXa will activate a small amount of
thrombin needed to allow for progression to amplification.
Amplification started with the initiation step providing the necessary materials of
activated FIX, FX, and importantly thrombin. The small amount of thrombin generated
during initiation activates FV, FVIII, and FXI. FXIa is a potent activator of FIX, and FVa
is an important cofactor for FXa (27, 28). FVIIIa is an important cofactor for FIXa and
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thrombin spurs its release from vWF to bind with FIXa. With these cofactor and factors
activated, it amplifies the quantity of pro-coagulation complexes to proceed into the
propagation phase (11, 29).
Propagation is a fully primed intrinsic/extrinsic response to generate fibrin. On the
platelet surface the tenase (Xase) complex of FVIIIa and FIXa activates FX to FXa. FXa
then forms the prothrombinase assembly with FVa to convert prothrombin to thrombin
(8). This functional prothrombinase assembly generates the thrombin burst. This
thrombin burst catalyzes the cleavage of fibrinogen into fibrin thus forming the clot at the
area of injury. The insoluble fibrin monomers aggregate together to form a soft clot.
Activation of FXIII to FXIIIa (Transglutaminase) then crosslinks the fibrin clots. This
cross-linking forms a rigid network trapping the platelets and erythrocytes inside, forming
the hard clot.
Termination, the fourth step of CBMC, is continually ongoing as it employs multiple
routes to keep the other three coagulation steps in check. This process ensures healthy
vasculature does not form random clots and dissolves the clots that have formed.
Formation of spontaneous clots could lead to clinical issues such as thrombus and
ultimately result in an embolism (21).
To accomplish this never-ending task, termination employs the Protein C/Protein S/
Thrombomodulin System (21). Protein C is an anticoagulant zymogen, when bound to
its cofactor thrombomodulin (TM) (5, 30-33). TM inhibits the clotting abilities of thrombin
and activates Protein C. Activated Protein C binds with cofactor Protein S to form the
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Protein C-Protein S complex that can terminate thrombin generation on platelets by
destroying FVa and FVIIIa (34, 35).
Fibrinolysis, the process of breaking down a formed clot occurs as part of normal
wound healing. The primary enzyme that breaks down the fibrin clot is plasmin. The
inactive pro-enzyme, plasminogen, flows throughout the blood and activates on contact
with the clot surface to form plasmin. Activation occurs by activator proteins called
tissue plasminogen activator (tPA) and single chain urokinase (scu-PA). Plasmin begins
to break down the fibrin resulting in full dissolution of the clot once the wound has fully
healed.

1.3 Serine Proteases
Hemostatic regulation occurs through the employment of coagulation factors known
as serine proteases. Serine protease production occurs in the liver’s hepatocytes and
then they circulate as zymogens in the blood. Proteolytic cleavage turns these inactive
enzyme precursors into active serine proteases. Minute differences allow them to
operate with the high degree of specificity to provide precision with regulation.
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All serine proteases share a great deal of similarity in gene sequence (29, 36, 37).
Sharing a high degree of DNA and amino acid similarity, protein folding delivers similar
structure patterns throughout the serine proteases. As demonstrated in the general
clotting factor structure shown in Figure 3. The
clotting proteases are composed of a catalytic head,
two Epidermal Growth Factor (EGF)-like domains,
and a Gla domain (29, 38, 39). This can be best
imagined if thought about as a Venus Flytrap.
The catalytic head resembles the digestive
enzyme trypsin and forms the “fly catching portion”
of the flytrap. The catalytic head contains the
protease domain to hydrolyze peptide bonds by
Figure 3 Structure of coagulation factor.

utilizing a “catalytic triad” of Serine, Histidine, and

The EGF1 and EGF2 domains are the

Asparagine (40-43). This “catalytic triad” is

“stem” portion holding up the catalytic

responsible for the activation of the next sequential

head. The “root” of the structure is the Gla

protease.

domain, that anchors the coagulation
factor to the phospholipid surface.

Holding up the catalytic head like a stem, are the
two EGF-like domains. The primary role of EGF-like domains is to hold the catalytic
head off the phospholipid surface and into the space above (41, 42, 44). This area also
contains some binding sites for regulators and co-factors of the enzyme. A flexible linker
attached to the two EGF-like domains holds the catalytic head (41, 42).
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The Gla domain refers to the conserved feature of amino-terminal carboxylated
glutamic acid residues that serve to anchor the entire structure (41). These modified
residues serve to anchor the entire structure via calcium bridging to the phospholipid
surface (38, 39, 44). The interaction of the Gla domain is possible by the Vitamin K
dependent, γ-carboxylase modification to the glutamate residues during synthesis in
hepatocytes of the liver (24).
The γ-carboxylation occurs via a quinone reductase that reduces Vitamin K to KH2.
Carboxylase enzyme cofactor Vitamin KH2 adds the carboxyl group to the Gla domain.
Calcium with a positive charge chelates via electrostatic interaction the negative charged
Gla domain and the anionic head group of phospholipids (25, 41).
Coagulation factors employ cofactors to assist in the protease activity. These
cofactors are comprised of factor specific cofactors in addition to the universal cofactors.
This relationship allows for pivotal coagulation cascade reactions to occur through
improved posturing of the factor/substrate orientation.
Universal Cofactors that are required by all serine proteases in the coagulation
cascade are calcium and an anionic phospholipid membrane. Radcliffe et al. found that
adding phospholipids and CaCl2 caused an 11-fold increase in activation of FVII (22).
Calcium serving as a cofactor with a positive charge chelates via electrostatic interaction
the negative charged Gla domain and the anionic head group of phospholipids (25, 41).
The interaction between the Gla domain and EGF-like domains is also highly dependent
upon calcium for orientation on the membrane in the vertical position of the serine
proteases, as described by Bode et al. 1997 (32). Krishnaswamy et al. also
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demonstrated evidence that substrate-membrane interaction considerably enhances
activation of FX by the extrinsic Xase complex (14, 45, 46). Without proper vertical
orientation and attachment to the phospholipid membrane the serine proteases exhibit
very reduced activity (45).
Though all serine proteases share a great deal of similarity in DNA and amino acid
sequence they are highly specific for activation, cofactor, and substrate (29, 36, 37).
Important cofactor/factor relationships that greatly increase protease activity are: FVIIa
to TF, FVIIIa to FIXa, and FVa to FXa. These specific relationships are what give way
for an optimal Km and Kcat.
As previously mentioned, the key role of FXa is to activate FII. FX activates
prothrombin via two methods and speeds: FXa alone slowly or at exponentially greater
rate with the cofactors in the prothrombinase complex. The prothrombinase complex
forms when there is vascular injury, and the platelet provides a phospholipid surface for
FXa, with cofactor FVa, acting on the substrate, Prothrombin. Specifically, FXa performs
activation of FII via proteolytic cleavage of two peptide bonds on the heavy chain, turning
FII into FIIa (46).
To best understand the role of serine proteases and their respective cofactors it is
important to look at Protein C, a serine protease whose function is to oppose
coagulation. Activated Protein C (APC) is crucial to the regulation of the clotting
cascade by acting on procoagulant serine proteases. Protein C shares similar structure
and generation to the Vitamin K dependent, pro-coagulant serine proteases synthesized
in the liver (30). APC in complex with cofactor Activated Protein S (APS), forms the
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APC/APS complex that is responsible for degradation of FVa and FVIIIa. Protein C is
activated by thrombin, and this activation is enhanced when thrombin is attached to
thrombomodulin. Thrombomodulin is a cofactor for thrombin found on the surface of
endothelial cells (34, 35). Walker et al. found that Protein C has a high degree of
specification and once activated cleaves both chains of the activated clotting enzymes,
FVa and FVIIIa (14, 30). Just as with FXa alone can activate a small amount of
prothrombin, it was identified that Protein C can inactivate FVa and FVIIIa
independently, but the Km is substantially decreased by the cofactors (30). Interestingly
it was discovered that the complex is not able to inactivate FVIIIa when, FVIIIa is
coupled with cofactor vWF (35).
FVIIa bound to TF in association with calcium on phospholipid surface forms the
extrinsic tenase complex and is the preliminary activator of FX (17, 22, 47). TF presiding
as the cofactor for FVIIa embraces the protease in optimal vertical orientation off the
membrane surface (48). McCallum et al. demonstrated the ability of the cofactor to be
so necessary for orientation it allows for prime positioning even if the Gla domain of
FVIIa becomes detached (18, 26, 49).
Kovalenki et al. investigated the activation of FX to FXa by the extrinsic tenase
complex and found that the size of the vesicle affected the rate of the reaction (50, 51).
This is important because it draws attention to the topographical and geometrical limits
of the factors while sitting vertically on the phospholipid membrane
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1.4 Factor IX
Factor IX (FIX)
shares similar homology
with other vitamin K
dependent clotting
factors produced in the
liver. It is an essential
clotting factor and a
deficiency in FIX can lead
to clinical issues such as
hemophilia B, also known
as Christmas Disease
(52, 53). Analyzing the
Figure 4 Structure of Factor IX in Ribbon View with protein structure.

DNA sequence data of

Photo by Jawahar Swaminathan and MSD staff at the European

the proband patient who

Bioinformatics Institute / Public domain

had a bleeding disorder

identified the disease as being a unique form of hemophilia. This mutation resulted in a
cysteine changed into a serine on the X chromosome within what is now identified as the
FIX gene (52-55).
The general structure of FIX shares a similar homology with the other serine
proteases (see figure 4). More specifically FIX is composed of two chains equaling 415
amino acids, a C-terminal heavy and N-terminal light chain (52). The C-terminal Heavy
chain of 235 amino acids forms from residues 181 to 415 (44). The N-terminal light
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chain consists of 145 amino acids (39). Together light and heavy chains are linked with
a disulfide bond at Cys-132 and Cys-189 (40-43).
This heavy chain contains the FIX catalytic head region as previously described in
the general description of serine proteases. The importance of the FIX catalytic head is
that it specifically contains the “Catalytic Triad” composed of Histidine-236, Serine-365,
and Asparagine-269 (40-43). This catalytic triad is responsible for the activation of FX.
The N-terminal light chain includes the Gla domain and two EGF-like domains (39).
The Gla domain of FIX is composed of the amino acid residues 1-38, which anchors the
enzyme with the calcium bridge to the phospholipid membrane of the platelet or other
phospholipid surface (39, 44). EGF-like domains are residues 47 to 84 and 85 to 127
(42). There is also a hydrophobic helix at residues 39 to 46, which acts as a support for
the EGF-like domains (41). Both EGF-like domains are stacked and joined with a
convex hydrophobic loop of EGF1 and a concave hydrophobic socket of EGF2 (41). A
flexible linker with residues 128 to 145 holds the catalytic head (41, 42).
Activation of FIX occurs by the intrinsic and extrinsic pathways. FXIa is the activator
in the intrinsic pathway model and FVIIa in the extrinsic pathway. FIX activation is in two
cleavage events performed by FVIIa/TF or FXIa (56). The first cleavage generates
FIXaα with a single cleavage removing Arg-180 to Val-181, followed by a second
cleavage removing Ala-146 to Arg-180 to generate FIXaβ (42, 57).
Fully activated FIXaβ forms the Xase complex, with specific cofactor FVIIIa and
universal cofactors. The role of FIX catalytic head is activation of FX by hydrolysis of
peptide bonds at Arg-194 to Ile-195 (40-43). This complex has been demonstrated to
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have 109-fold increase in the procoagulant activity compared to active, non-complexed
FIXa, as reviewed by Neuenschwander et al. (56, 58).
The anticipated height of FIXa is a distance between 50 to 100 Å above the
membrane. A review and understanding of the FIXa structural dependency on cofactors
is fundamental. X-ray crystal structures have demonstrated the ability of cofactors and
ions to change the conformation of factors in the clotting cascade. Length changes of
the serine protease, specifically FIX have been demonstrated with cofactors. Bode et al.
and McCallum et al. determined how the interaction between the EGF1 domain and Gla
domain is highly dependent upon calcium (41, 59). When there is a lack of calcium the
protease is no longer able to chelate to the phospholipid surface. Also, through small
angle x-ray and NMR studies, a change in orientation based on calcium has been
detected (41, 44). The EGF-like domains’ binding sites for cofactor FVIIIa act upon the
final structure of Xase complex. When bound, they promote activation of FIX by holding
in the vertical orientation (41). While all of these studies point to the orientation of the
complex, none are capable of addressing the specific optimal distance and orientation of
the catalytic head with regard to stretch and flexibility of the factor (60).

1.5 Anti-Coagulation and Inhibitor Structure
Anticoagulants are chemicals used in the prevention of blood clotting by acting on
clotting factors within the Coagulation Cascade. Anticoagulants have a long history of
uses throughout evolution by animals such as mosquitos to obtain blood from the host
animal (61). Currently, anticoagulants are used as therapies in patients, for example
with atrial fibrillation to prolong an individual’s survival. Most of the current anticoagulant
therapies used in medical practice involve coumarins and heparins (62).
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Looking at the mechanism by which coumarins work it is important to look
specifically at the drug Warfarin. Warfarin first used by man as a rat poison was later
approved for use as an anticoagulant by acting as a Vitamin K analog (63). Vitamin K
activity is impeded by Warfarin interacting with Vitamin K epoxide reductase. Without
enough active Vitamin K to carboxylate the Gla residues on Vitamin K dependent serine
proteases they are no longer able to chelate the phospholipid surface (21, 44). This is a
common way to prevent blood coagulation but has negatives to its uses such as a drug
loading time, taking around 72 hours before effects are seen in a patient.
The polymer, heparin is another common anticoagulant used by medical
professionals in things such as blood filtration procedures and surgeries. Heparin is
naturally produced in the body by basophils and mast cells and can be extracted for
pharmaceutical uses from mammals such as cattle and pork. Heparin works by binding
and increasing activity of Antithrombin III (AT) (15, 32, 61, 64-66).
Antithrombin (AT) belongs to a class of inhibitors known as serine protease inhibitors
or serpins. Serpins contain a serine residue in their catalytic triad to help regulate the
proteolytic clotting cascade. A principal class of serpins is Kunitz Protease Inhibitors,
which includes AT. AT is a small glycoprotein produced in the liver, which binds to the
serine residue in the active catalytic triad of thrombin, leaving it inactive. Other common
serpins of FXa and FIXa are Basic Pancreatic Trypsin Inhibitor (BPTI) and Protease
Nexin-2, respectively, via their Kunitz Protease Inhibitor domains (58, 67). To tie this
together heparin has also been shown to increase the rate of AT and FIXa inhibition in
the presence of Ca2+ (58).
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2 Research Design
As discussed, blood coagulation requires the use of enzymes orchestrated in a
series of highly specific events. For these events to occur at a tremendous exponential
rate, the enzymes require their respective cofactors and a phospholipid membrane. It
has also been determined that the topographical characteristics of the activation
complex on the phospholipid membrane are also essential. Fluorescence studies have
delved into the distance of closest approach to the membrane of the active site for
several of the coagulation serine proteases (42-44, 49, 59, 60, 68, 69). In several
instances, it was documented that the non-enzymatic cofactor binding altered the
distance. With distance above the membrane correlated to the overall length of the
serine protease as determined by x-ray crystal structures, it is reasoned that proteases
orient vertically on the membrane with little to no bending (Figure 5). This reasoning has
not been proven using fluorescence resonance energy transfer (FRET)-based studies as
these are only capable of showing the distance of closest approach. FRET cannot
determine the optimal height/distance needed for maximum coagulation activity. Also,
lacking in the gap of knowledge is the potential for elasticity and their ability to stretch off
the membrane, proving to be a significant gap in knowledge. The goal of this study to
gain insight into the optimal reactive height of coagulation factor IXa above the
phospholipid surface by the generation of a lipid Anchored Molecular Ruler with
attached Inhibitor (AMRI).
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The enzymatic
characterization of
coagulation factors has
been frequently studied
through use of small
peptide inhibitors such
as serpins, as they sit
directly in the catalytic
site of the enzyme (38,
Figure 5 Demonstration of knowledge lacking in the optimal
reactive height of FIXa. This looks at Crystal Structure Data (A)
and FRET (B). The Crystal structure gives us the height at a
moment frozen in time. FRET data gives the distant of closest
approach. Lacking is the information on the wobble (C) and the
stretch (D) to understand how the Factor moves in a fluid
environment for optimal reactivity.

70-73) . Hence, we
are using it in the
AMRI. To generate
AMRI, a protein
anchoring sequence of
Leucine, Alanine,

Glycine, and Cysteine (LAGC) is used to fixate the entire structure to a lipid surface. To
direct the lipid-bound protein for anchoring, LAGC will be coupled with a leader
sequence for shuffling into periplasmic space, originally from the Apyrase gene of
Shigella, for protein collection. A height adjustable linker area is then required between
the anchor and inhibitor regions of AMRI to ensure the proper height of inhibitor.
Employing the linker sequence EAAAK, with a rigid slantwise fixed height of 7.5 Å per
sequence, will allow for the creation of a specific height for the engineered protein (74).
Based on the Crystal structure data the hypothesized reactive height is a distance
between 50 to 100Å above the membrane (6, 42, 43, 69). Completing the protein's linker
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region will be a flexible linker at the end of a rigid set to ensure the inhibitor properly fits
in FIXa active site. Finalizing the AMRI complex will be a PN2-KPI inhibitor, which has
previously been demonstrated to inactivate FIXa.

2.1 Protease Nexin2 - Kunitz Protease Inhibitor (PN2-KPI)
Anchored Kunitz-based inhibitors bound to lipid membranes have been successfully
utilized for analysis of serine protease activity using Surface Plasmon Resonance (SPR).
SPR allows for measurement in a real-time binding of two molecule companions without
the need of labels by detecting the changes in refractive index (GE Healthcare,
Technology Note 23: Label-free interaction analysis in real-time using surface plasmon
resonance. (2007) BR-9004-63 28-9214-39 AA.). The researchers generated a
phosphatidylcholine (PC) lipid monolayer containing nickel chelating head groups and
successfully attached 6-histidine-tagged bovine pancreatic trypsin inhibitor (BPTI). Over
the attached BPTI lipid layer, soluble proteases flowed over and were bound,
establishing proof that a bound Kunitz inhibitor is capable of remaining functional after
attachment. However, these studies found that binding rates were drastically lower than
in other studies using solution-phase testing (56, 58). One explanation of this is the
desired orientation of proteases on the membrane and the close position of the inhibitor
on the membrane. This negative steric interaction is the reasoning for wanting the
Kunitz inhibitor attached at a set distance above the membrane and allowing more
favorable binding to the protease domain.
The Kunitz Protease Inhibitor domain of Protease Nexin 2 (PN2) was employed to
bind to the active site of FIXa (56, 71). The precursor form of this protein, PN2-Amyloid
β Protein Precursor (AβPP) was found to have a role in the regulation of specific
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proteases in extracellular environments; specifically, with plaque deposits of those
affected with Alzheimer's disease and Down syndrome (72). Schmaier et al. found that
PN2-AβPP was 71-fold more effective in ability to inhibit FIXa than antithrombin III (70,
71). Neuenschwander et al. experimentally determined that using just the inhibitor
domain of PN2 (PN2-KPI) displayed an increased affinity for FIXa (58). PN2-KPI is a
more ideal inhibitor for height determination of the FIXa active site.

2.2 LAGC anchor with Apyrase leader sequence
Hydrophobic anchoring of a protein to a lipid membrane is not a novel idea, but an
evolved mechanism. In unicellular organisms many membrane proteins utilize the
Lipobox motif to anchor to the phospholipid. Roughly 75% of all lipobox sequences
consist of the amino acid sequence, LAGC. The cleavage between the Glycine and
Cysteine results in the formation of an N-terminal Cys. The SH group on the new Nterminal Cys is acted on by diacylglycerol transferase, creating the diacylglyceryl moiety.
This moiety with Cys incorporated serves as the anchor to the phospholipid surface so
that the attached protein does not diffuse away (75).
Bhargava et al. identified a 23 amino acid leader sequence for virulent apyrase gene
that is responsible for translocation of the protein from the cytosol to the periplasmic
space in Gram-negative bacteria. Identification was possible via cloning and expression
of Shigella flexneri 2a apyrase gene in an E. coli plasmid (76). Apyrase was directed to
exit the cytosol and travel to the periplasmic space through translocase. The leader
sequence on the N-terminal end is recognized and transported to the periplasmic space.
The clone was then sequenced against the wildtype for confirmation of the apyrase
gene.
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Kamalallannan et al. demonstrated an engineering process for converting a nonlipoprotein into an anchored lipoprotein (75). Using the Shigella apyrase leader
sequence for transport, anchoring with LAGC sequence combined with normal protein
sequence generated a viable lipid bound protein. With the Cys serving as the anchor on
the N-terminus end, it allowed for regular protein expression on the C-terminal end.

2.3 Linkers= (EAAAK)11 (GGGGS)
Linker construct has become an essential tool in the development of protein fusion.
The ability to link proteins and not interfere with their reactivity is vital and achieved by
taking into consideration flexibility and hydrophilicity (77, 78). The sequence EAAAK,
whose parent strand, initially described by Marqusee and Baldwin in 1987, is referred to
as a rigid linker, forming alpha helices (78). This helix is stabilized by Glutamic acid and
Lysine salt bridges and internal Hydrogen bonds (74, 77-79). Arai et al. determined that
it was possible to control the distance between two proteins by manipulating the
repetition of the EAAAK motif (77, 80). Amet et al. described the use of EAAAK linker
sequence by varying the number of sequence repeats to optimize reactivity of an
expressed protein (81).
As the number of EAAAK motif repeats increases, so does the strength and
tightness of the alpha helix structure (80). Through FRET studies and high-resolution
models, it also determined that the linkers connect diagonally and not longitudinally
creating a vertical increase of 7.5 Å and not the interdomain distance of 10 Å, with
(EAAAK)5 having a distance of 43.86 Å (74, 77, 80). It was concluded that the rigid
linkers provided a lesser degree of distance fluctuation between the N and C terminus.
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Li et al. also confirmed through molecular dynamic simulation that EAAAK in helical form
is in the lowest energy state, indicating conformational stability (74).

10

7.5 Å

Å

The GGGGS sequence is a well-known flexible linker with many applications in

Figure 6 Structure formations of EAAAK and GGGGS. This demonstrates how the proposed
protein structure will be rigidly lifted from the phospholipid membrane, while GGGGS provides
the flexible conduit for proper insertion of the inhibitor

protein engineering. This flexible nature allows for the mobility of the inhibitor and the
tethered EAAAK rigid sequence. In the Li et al. 2015 study on molecular dynamics, it
was found to have no energy change in the 29ns simulation and produced total energy
fluctuation the entire time (74). This is indicative of a protein with no conformation
stability. The flexible linker also produced an increase in variable distances in the FRET
analysis conducted (74, 80). Incorporation of the flexible linker at the end of the rigid
linker sequence supplies a lack of conformation, making it ideal to serve as the
"intermediary" between the rigid linker and inhibitor. This lack of conformity will provide
the inhibitor with freedom of movement to fit within the catalytic head of FIX.
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4 Specific Aims

The focus of this study is to generate a lipid Anchored Molecular Ruler with attached
Inhibitor (AMRI) at a fixed height to quantify the optimum reactive height for FIXa. The
hypothesized reactive height is a distance between 50 to 100Å above the membrane.
Specific Aim 1: Creation of an AMRI in an expression vector.
Specific Aim 2: Purification of AMRI in an expression vector.
Specific Aim 3: Sequencing of AMRI in an expression vector.
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5 Methods

5.1 SnapGene

SnapGene® software (from GSL Biotech; available at snapgene.com) was used for
vector mapping and design. The PCR primers and oligonucleotides were designed with
the program including the LAGC anchor region to attach to a phospholipid membrane;
an EAAAK (EA3K) rigid linker serving as a molecular ruler; a PN2-KPI region serving as
the FIXa inhibitor; the PCR primers needed to correct the orientation of the current pLAGC-EAK10 plasmid.

5.2 Vector Preparation
5.2.1 Description

pET11d plasmid was used for the cloning backbone. The p-LAGC-EAK10 plasmid
was a gift from a previous GA-PCOM thesis student. This plasmid contained the
Shigella apyrase leader sequence, anchor sequence LAGC, and the molecular ruler
sequence of EAAAK repeated 10 times inserted between the NcoI and HindIII restriction
sites.
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5.2.3 Growth

Streak plates of DH5α Escherichia coli (E. coli) were made with LB agar (10 g/L
tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L Difco Granulated agar, pH 7.0)
containing ampicillin with a concentration of 50 µg per ml (82) . The plate was placed in
37°C incubator overnight and removed after growth and placed in 4°C for storage.
Individual isolated colonies were chosen and inoculated into 5 ml culture tubes,
containing LB media. Ampicillin ensures the selection of only E. coli containing any
vector with the gene conferring Ampicillin resistance; inhibiting growth of E. coli lacking
ampicillin resistance. The culture tube was then placed in a 37°C incubator at 250 rpm
overnight. This growth was to ensure a good cloudy density of bacterial growth. 1 mL of
the initial 5 mL culture was used to inoculate 250 mL and 500 mL LB media cultures.

5.2.4 Transfection

Competent DH5α E.coli cells were used for transfections and were a gift from Dr.
Frank Jenney. The DH5α cells were taken from the -80°C freezer and placed to thaw on
ice. The cells were then stirred with the tip of a pipet, before pipetting 70µl into a prechilled 1.5 ml tube. There as one tube per each individual reaction. 10 ng of plasmid
DNA was placed into the 70 µl of competent cells and stirred with a pipet tip. This
mixture was then placed on ice to incubate for 30 minutes, followed by 30 seconds of
incubation at 42°C to heat shock the cells. The tubes were immediately transferred and
chilled on ice for 2 minutes. Next, 300 µl SOC (20 g/L tryptone, 5 g/L Yeast extract, 0.5
g/L NaCl, 10 ml/L 250 mM KCl, 5 ml/L 2 M MgCl2, 20 ml/L 1M glucose, pH=7.0)
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prewarmed to 37°C was added to the cell mixture and allowed to shake for 1 hour at 100
RPM. The cells were then plated 100µl and 200µl on LB plates, both with and without
the 50 µg/mL ampicillin selection agent. In these experiments, different molar ratios of
the digested vector and insert were used to obtain optimum transfection efficiency.
Experimental molar ratios of 1:3 and 1:6 vector to insert were used. Controls included
vector plus ligase only, and DH5α cells only. Once plated the plates were allowed to dry
before placing inverted at 37°C overnight. Isolated colonies on the successful plates
were then inoculated into an LB broth with ampicillin as described above.
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5.2.5 DNA Miniprep

DNA Miniprep was performed to screen for the intended clone at various stages of
the cloning process. Quantum Prep® Plasmid Miniprep Kit (Bio-Rad Laboratories Inc.,
Hercules, California, Catalog #732-6100) was used in all Miniprep procedures. During
this process, centrifugation was performed at the maximum speed of 13,300 x g on a
tabletop centrifuge. Using 1 to 2 ml of the growth culture the protocol was followed
depending on the desired final concentration of pure plasmid. The culture was placed in
a microcentrifuge tube to pellet the cells and ran for 30 seconds. With the cells pelleted
the supernatant was removed by pipetting. Then another quick spin on a small desktop
centrifuge was performed just to ensure removal of supernatant. The pellet was
resuspended using 200 μl of the Cell Resuspension Solution provided by vortexing and
pipetting up and down. Next 250 μl of the Cell Lysis Solution were added and mixed by
gently inverting the capped tube about ten times. The Cell Lysis Solution was followed
by the addition of 250 μl Neutralization Solution then inverted 10 times for complete
mixture. A precipitate formed and was then placed back in the centrifuge for 5 minutes
to collect the cell debris. The plasmid DNA, located in the clear lysate, was transferred
to a spin filter, and combined with 200 μl mixed Quantum Prep Matrix, with the filter
placed in a 2 ml centrifuge tube. The tube with the filter was centrifuged for 39 seconds.
The spin filter was removed, and filtrate discarded, then put back in the centrifuge tube
and washed twice with 500 μl of Wash Buffer. The first wash was centrifuged for 39
seconds and the second was for 2 minutes. An additional spin was performed if a slight
smell of ethanol persisted. The filter was then placed in a 1.5 ml microcentrifuge tube

29
and eluted for 1 minute with 100 μl of prewarmed 70°C nuclease-free water. The
purified DNA was then either stored at -20°C or used immediately.

5.2.6 DNA Midiprep

Quantum PrepTM Plasmid Midiprep Kit (Bio-Rad Laboratories Inc., Hercules,
California, Catalog Number 732-6120) was used for collection of larger pure plasmid
DNA amounts. All centrifugation was in a swing bucket table-top centrifuge using 250 ml
Oak Ridge tubes. 250 ml growth media was centrifuged at 5,000 × g for 10 minutes to
pellet the cells. The tubes were then drained of supernatant and inverted on a paper
towel to ensure removal of media. The pellet was resuspended with 6 ml Cell
Resuspension Solution and mixed by vortexing until all cells were back in solution. Next,
6 ml of prewarmed 37° Cell Lysis Solution were added and mixed by rolling on the
benchtop. This mixture was allowed to sit for 3 minutes at room temperature before
adding 10 ml Neutralization Solution and mixed by inverting 5 times. After 3 minutes a
white flocculant formed. This solution was then placed in a PureYieldTM Clearing
Column and a new 50ml disposable Falcon plastic tube, then allowed to sit for an
additional 2 minutes at room temperature before centrifuging at 2,500 × g for 10
minutes. Then filtered lysate was transferred into a PureYieldTM Binding Column and
new 50ml disposable Falcon plastic tube to which 5.0 ml of Endotoxin Removal Wash
Solution were added. This was centrifuged at 1,500 × g for 3 minutes, and the flow
through was discarded. Following the Endotoxin Wash were two washes of 20ml of
Column Wash Solution, discarding the flow through each time. At the completion of the
second wash, the column tip was tapped dry on a paper towel and placed in a new
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Falcon tube and spun for 15 minutes at 1,500 × g. The column was then allowed to sit
for 5 minutes or until no smell of ethanol remained. Next, the column was placed in a
new Falcon tube, and 600 μl of prewarmed 70°C nuclease-free water was allowed to sit
on the column membrane to rehydrate. After 2 minutes the tube was centrifuged for 5
minutes at 1,500 × g. The filtrate was collected and placed in a 1.5 centrifuge tube.

5.3 DNA Analysis

5.3.1 Thermo Nanodrop Spectrophotometer

The ThermoFisher Scientific Nanodrop Spectrophotometer, now referred to as
NanoSpec, was started using the setting for double-stranded DNA and was calibrated
using only 2 μL of nuclease-free water. Then 2 μL of DNA sample was added to the
NanoSpec to determine concentration (ng/μL). The NanoSpec made measurements by
wavelength absorbance at 260 nm for Nucleic Acids and 280 nm for proteins. This
A260/A280 ratio reading was calculated to determine DNA purity; a ratio of close to 2.0 is
considered pure for DNA, however anything above a 1.8 was considered acceptable for
use.

5.3.2 Agarose Gel Electrophoresis

A 1% agarose gel (10 mg/mL of Nuclease-free agar in 1X TAE Buffer (Tris-acetateEDTA, pH 8.3)) was separated using 0.1 µL/mL GelRed™ Nucleic Acid Gel Stain
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(Phenix Research Products, Candler, North Carolina) in 1X TAE running buffer. For
tracking the progression of DNA in the agarose, 5 μL Quick-Load 2-Log DNA Ladder
(New England BioLabs, Ipswich, Massachusetts, Catalog # N0550S) was employed for
size analysis and each loaded sample had 5 μl of Gel Loading Dye, Purple (6X), no SDS
(Catalog # B7025S) per 25 μl reaction volume. The DNA and loading dye mixture were
mixed well on Parafilm before being loaded into the desired well in the agarose gel.
Once the desired amount of DNA was loaded into the agarose gel wells, including the
ladder, the current was started at 100 Volts and ran for approximately 45 to 95 minutes
depending on the tracking of the red band generated by the purple load dye. The red
band tracks through the 1% agarose gel as a piece of DNA with approximate length of
300 base pairs. This was important for direction, speed of travel, and to determine time
run time for proper separation of different sized bands. This same method was
employed for DNA band isolation for determining digested and undigested plasmid DNA.
To determine the DNA amounts gel quantification was applied to either verify the
concentration determined by the NanoSpec or used as a stand-alone result.

5.3.3 Sequencing

Sequencing performed in this project was conducted by Retrogen Incorporated in
San Diego, California. The primer used in sequencing was against the T7 tag vector
sequence. The data generated by Retrogen was then imported into the SnapGene®
software for alignment analysis.
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5.4 Resuspension of Lyophilized PN2 oligonucleotide

Lyophilized samples of the forward and reverse PN2 oligonucleotides were ordered
from Integrated DNA Technologies. When received the samples appeared translucent
and were virtually undetectable to the naked eye. The samples were first centrifuged at
maximum speed for 1 minute before opening the tops of their centrifuge tubes. Then
concentrated stock for each were resuspended at a concentration of 100 µM and a
working stock concentration of 10 µM; both made with TE Buffer (10mM Tris; 0.1 mM
EDTA; pH 8.0). The following oligonucleotides were generated by Integrated DNA
Technologies, Inc. (Skokie, Illinois):

5.5 Design of PN2

The forward and reverse oligonucleotides were ordered with the plan to anneal them
together. Thus, the annealed double stranded product would constitute the sequence for
to the PN2 inhibitor with overhangs matching the HindIII and EcoRI restriction sites.
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5.5.1 PN2 forward
Sequence - PN2 forward 20 nmole Ultramer® DNA Oligo, 186 Bases
5- /5Phos/AAT TAA GCA GAA CCA CAA ACA GCC ATA CAG TAC TCC TCA
GTG TCG AAG TTG TTT CTG TTA CCA CCA CAA CCA CCG TAG AAG AAT GGA
GCA CAC TTA CCC TCA GTA ACG TCG AAG TAC CAT CTA GAA ATC ATA GCT
CTA CAT GGA CCA GTC TCA GCT TGC TCA GAA CAA ACC TCT CTA ACA ACC
TCC -3
Properties:
Tm (50 nM naCl): 70.7 °C
GC Content: 45.2%
Molecular Weight: 57016.9
nmoles/OD260: 0.6
ug/OD260: 31.6
Ext. Coefficient: 1803400 L/(mole·cm)
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5.5.2 PN2 reverse
Sequence - Pn2 reverse 20 nmole Ultramer® DNA Oligo, 186 Bases
5- /5Phos/AGC TGG AGG TTG TTA GAG AGG TTT GTT CTG AGC AAG CTG
AGA CTG GTC CAT GTA GAG CTA TGA TTT CTA GAT GGT ACT TCG ACG TTA
CTG AGG GTA AGT GTG CTC CAT TCT TCT ACG GTG GTT GTG GTG GTA ACA
GAA ACA ACT TCG ACA CTG AGG AGT ACT GTA TGG CTG TTT GTG GTT CTG
CTT -3
Properties:
Tm (50 nM naCl): 70.8 °C
GC Content: 46.2%
Molecular Weight: 57940.3
nmoles/OD260: 0.6
ug/OD260: 32.3
Ext. Coefficient: 1793300 L/(mole·cm)
Annealing of forward and reverse PN2-KPI primers results in following structure:
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5.6 Restriction Digest

New England Biolabs restriction enzymes, XbaI (Catalog #R0145S), NcoI-HF
(Catalog #R3193L), HindIII-HF (Catalog #R3104L), EcoRI-HF (Catalog #R3101L), and
Alkaline Phosphatase, Calf Intestinal (CIP) (Catalog #M0290L), had incubation
temperatures of 37°C in NEBuffer CutSmart buffer. All restriction enzymes could be
heat inactivated at temperatures of 80°C, except for Calf Intestinal Phosphatase (CIP).
Therefore, all reactions were performed in a ThermoFisher Applied Biosystems™
Veriti™ 96-Well Thermal Cycler under controlled conditions. The heat inactivation of
XbaI was 65°C, but for the simplicity of programming 80°C was used. The reaction
conditions XbaI (Catalog #R0145S), NcoI-HF (Catalog #R3193L), HindIII-HF (Catalog
#R3104L), EcoRI-HF (Catalog #R3101L) were as follows:
Restriction Enzyme

20 units

DNA

Up to 1 µg

10X NEBuffer CutSmart

5 µl (1X)

Total Reaction Volume

50 µl

Incubation Time

3 hours

Incubation Temperature

37°C

Heat Inactivation Time

20 minutes

Heat Inactivation Temperature

80°C

Once the first restriction digest was completed the DNA was purified by gel
electrophoresis and extracted as described. The next restriction was only heat
inactivated before with the Calf Intestinal Phosphatase (CIP) treatment
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The CIP treatment was performed to remove the 5’-phosphate by the addition of 20
units of CIP to the previously heat inactivated digest. The ThermoFisher Applied
Biosystems™ Veriti™ 96-Well Thermal Cycler was programmed to run for 1 hour at
37°C to allow the phosphatase to cleave. Afterwards, the temperature dropped in the
ThermoFisher Applied Biosystems™ Veriti™ 96-Well Thermal Cycler to 4°C until
removed. After the CIP treatment, a Phenol-Chloroform-Isoamyl Extraction with Ethanol
precipitation to stop the phosphatase was performed.

5.7 Purification

5.7.1 Phenol-Chloroform-Isoamyl Extraction

To remove the restriction enzymes and ensure that the DNA is free of proteins and
lipids it is essential to perform an extraction. Once the extraction is performed the
purified DNA is then able to be used in the next phase of the experiment. The DNA
mixture was mixed with one volume of phenol:chloroform:isoamyl alcohol in a ratio of
25:24:1, respectively. The solution was then vortexed thoroughly for approximately 20 to
30 seconds, followed by centrifugation at room temperature for 2 minutes at 13,300 x g.
Next, the upper aqueous layer was removed and transferred to a fresh tube, being
careful to not get phenol during pipetting. To ensure the removal of all phenol another
wash was performed with equal volume of chloroform, then vortexed for approximately
20 to 30 seconds, followed by centrifuging at room temperature for 2 minutes at 13,300 x
g. The upper aqueous layer was transferred to a fresh tube for ethanol precipitation.
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5.7.2 Ethanol Precipitation

The microcentrifuge tube containing the DNA solution had 3M Sodium Acetate
added at 1/10 volume, then vortexed to ensure mixture of salt with DNA. Next, 2X
volume ice-cold 100% Ethanol was added and vortexed to provide a complete mixture.
The mixture was placed in -80°C for at least 1 hour but typically left overnight. When the
mixture was removed, the mixture was centrifuged at 13,300 x g for 20 minutes at 4°C.
The supernatant was then decanted carefully to not disturb the pellet. Next, the pellet
was washed with 70% ice-cold ethanol and allowed to stand at room temperature for 5
minutes. The tube was then centrifuged again at 13,300 x g for 20 minutes at 4°C, and
the supernatant was removed by pipetting. The pellet was then air dried for
approximately 20 to 30 minutes or until no trace smell of ethanol existed. The dried
pellet was then resuspended with 20-40 μL Nuclease-free water or 1X TE buffer via
gently pipetting. The resuspension was incubated at 37°C for 15 to 20 minutes to
ensure resuspension.
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5.8 Ligation

New England Biolabs T4 DNA Ligase (400,000 cohesive end units/ml; Catalog #
M0202L) was used in all ligations. The protocol was set up as follows:
Vector DNA

1.000x10-5-2.000x10-5 nmol

Insert DNA

3.000x10-5-5.000x10-5 nmol

T4 DNA Ligase

400 Units

T4 DNA 10X Ligase Buffer

2µl

Nuclease-free water

Up to 20 µl

Total Reaction Volume

20µl

Vector DNA to Insert DNA was set up at a 1:3 or 1:6 molar ratio. This reaction was
set up on ice and the T4 ligase added last. The reaction was placed in the
ThermoFisher Applied Biosystems™ Veriti™ 96-Well Thermal Cycler for 14 hours at
16°C. The reaction was stored in the 4°C refrigerator or on ice until used in the
transfection.

5.9 Polymerase Chain Reaction

The following PCR primers generated by Integrated DNA Technologies, Inc. (Skokie,
Illinois) were used for sub-cloning the original insert with the restriction sites in a different
reading frame orientation.
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5.9.1 Primer #1: HindIII replacing NcoI-NT
The 34 Bases of Sequence - HindIII replacing NcoI-NT were 5’- ATA CAA AGC
TTC ATG GGC TAC CAC CAC CAC CTT T -3’. Properties of the designed primer
sequence were:
Tm (50 nM NaCl): 65.2 °C
GC Content: 47.1%
Molecular Weight: 10290.7
nmoles/OD260: 3.1
ug/OD260: 32.4
Ext. Coefficient: 317900 L/(mole·cm)
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5.9.2 Primer #2: NcoI Replacing HindIII-OT
The 42 bases of Sequence - NcoI Replacing HindIII-OT were 5’- ACA CCA TGG
AGC TTA TGA AAA CCA AAA ACT TTC TTC TTT TTT -3’. Properties of the
designed primer were:
Tm (50 nM NaCl): 61.9 °C
GC Content: 31%
Molecular Weight: 12805.4
nmoles/OD260: 2.5
ug/OD260: 31.9
Ext. Coefficient: 400800 L/(mole·cm)

The oligonucleotides were resuspended in TE buffer (10mM Tris; 0.1 mM EDTA; pH
8.0) with a 100 μM concentrated resuspension and a 10 μM working stock working stock
concentration

41
The Polymerase Chain Reaction mixture was set up as follows using the Q5® HF
polymerase kit (New England Biolabs; Catalog # M0492S).
Final
Concentration
Q5 HF Master Mix 2X

1X

10 µM of Primer #1: HindIII replace NcoI-NT

0.5 µM

10 µM of Primer #2: NcoI replace HindIII-OT

0.5 µM

PLE10 Template DNA

1 pg

Nuclease-Free Water

Up to 50 µL

Total Volume

50 µL

This mixture was placed in a PCR reaction tube. The ThermoFisher Applied
Biosystems™ Veriti™ 96-Well Thermal Cycler ran using the program NPB Q5 HF
method 2, which was programmed as follows:
Step

Temperature (°C)

Time (seconds)

Denaturation

98

30

35 cycles

98

10

72

60

Final Extension

72

120

Hold

4

∞
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Once the PCR was completed the PCR tubes were pooled and placed in 4℃
refrigerator. Analysis of the PCR product was performed with the NanoSpec to
determine DNA concentration of the PCR products.

5.10 DNA extraction from Agarose Gels

QIAEX II® Gel Extraction Kit (Qiagen; Hilden, Germany; Catalog # 20021) was used
to harvest DNA from agarose gels. The manufacturer's protocol was followed but
modified to fit specific requirements.
DNA product was loaded into the well of a 1% TAE agarose gel that was contained
in a Gel Electrophoresis Chamber and electrophoresed at 100 volts for roughly 60
minutes. The 1% TAE agarose gel, containing electrophoresed DNA product, was
imaged with an UV gel imager. The individual bands were excised while under UV light
to determine precise location using a sharp scalpel blade. If DNA banding patterns were
not clearly distinct to separate based on size compared to the NEB Quick-Load 2-Log
DNA Ladder and other DNA products in same lane, then the gel was placed back into
the Gel Electrophoresis Chamber in 10-minute increments until optimal separation was
obtained. To maximize the recovery all agarose lacking DNA was removed from the
excised band, so the weight of agarose was approximately 250 mg. The agarose
containing DNA was placed in an empty, pre-weighed 2 ml microcentrifuge tube, and
weighed to determine mass. Next, 2 volumes of Buffer QX1, 2 volumes of nuclease-free
H2O, and 30 µl of QIAEX II solution were added to 2 ml microcentrifuge tube. The
QIAEX II solution was vortexed exceptionally well to ensure proper mixture before
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adding to the buffer containing the agarose. After addition of QIAEX II, the solution was
incubated at 65°C for 12 minutes, and vortexed every 2 minutes. Intermittent vortexing
allowed proper binding of QIAEX II to the DNA. Next, the solution was centrifuged for 30
seconds at maximum speed, and the supernatant was removed with a pipet. A pellet
wash was performed with 500 µl of Buffer QX1 and vortexed to resuspend the pellet.
The supernatant was pipetted and discarded after a 30-second centrifuge. Next, the
pellet was washed twice with 500 µl of Buffer PE. For each wash, the pellet was
vortexed to resuspend in solution, then centrifuged to pellet the QIAEX II beads and
supernatant was removed. After final wash was completed, the pellet was air dried for
30 minutes or until the pellet was white. With a dry white pellet, the DNA was eluted with
40 µl of nuclease-free H2O, vortexed the pellet to resuspend, and incubated at 70°C for
15 minutes. The resuspended pellet was stirred with a pipet tip and incubated an
additional 5 minutes. The DNA yield was increased by a final maximum speed
centrifugation that lasted a minimum of 30 seconds, but less than 45 seconds. This last
step eluted additional DNA into the nuclease-free water. Next the nuclease-free water
that contained eluted DNA was pipetted into a new centrifuge tube.
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6 Results

6.1 Dissection of pET11D

E.coli DH5α was chosen as a
plasmid maintenance host of pET11D.
Figure 7 demonstrates a vector map of the
pET11d plasmid isolated from the bacterial
cell. The plasmid contains multiple
restriction sites that were selected based
on location and orientation to the ribosome
binding site (RBS) and the open reading
frame (ORF).
The gene encoding LAGC(EAAAK)11, to be named AMR, was
previously cloned into the pET11d plasmid
and was gifted from a former Georgia

Figure 7 pET-11d Vector Map with a length of 6,674 base
pairs. The restriction sites used are identified with names
and locations on the vector. Also noted is the Open
Reading Frame direction and location of the Ampicillin
Resistance Gene.

Campus – Philadelphia College of
Osteopathic Medicine Thesis Student, Robin Conley (83). The Apyrase leader sequence
directs translocation of the LAGC sequence from the cytosol to the periplasmic space of
the E.coli and is then cleaved by the cellular machinery. The LAGC, a portion of the
lipobox protein, serves as a signal sequence that is cleaved, then modified with an Nacetyl moiety. Each EAAAK motif forms a rigid alpha helical structure which will extend
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from the N-acyl-S-diacylglycerylcysteine lipid anchor moiety. To achieve the desired
distance between the inhibitor moiety and the phospholipid anchor, the EAAAK motif
was repeated a total of eleven times. Encoded at the terminus of the EAAAK region is a
GGGGS flexible linker sequence. The flexible nature of GGGGS allows for the mobility
of the inhibitor, instead of being directly tethered to the rigid EAAAK sequence

6.2 PCR Reorientation and Purification of AMR

Figure 8 pET-11d Vector Map with the LAGC-EAAAK sequence inherited from a previous student.. The
restriction sites used are identified with names and locations on the vector. Also noted is the Open Reading
Frame direction and location of the Ampicillin Resistance Gene.

The gifted plasmid, p-LAGC-EAK11, contained the Shigella apyrase leader
sequence, anchor sequence LAGC, repeated ruler sequence EAAAK and flexible linker
sequence GGGGS inserted between restriction sites NcoI and HindIII (see Figure 8).
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Employing the p-LAGC-EAK11 plasmid as the cloning backbone for the PN2 inhibitor, indepth analysis determined the reading frame directionality was incorrect. Correct
placement of AMR sequence is necessary for not only protein expression but for the
addition of the PN2-KPI inhibitor.
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Figure 9 Master Plan Overall View. Correction of pET-11d Vector with the LAGC-EAAAK (AMR) sequence
inherited from a previous student. Redesign of the PN2-KPI and insertion into the vector to produce the final
product, AMRI. The restriction sites used are identified with names and locations on the vector. Also noted
is the Open Reading Frame direction and location of the Ampicillin Resistance Gene.
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A master plan (see Figure 9) was developed to use PCR to re-engineer the
restriction sites and correct the AMR reading frame orientation by subcloning out the
previous bits and swapping their orientation before adding the
KB
10

PN2-KPI sequence. The new reverse strand, named ‘HindIII
replacing NcoI-NT’, and the new forward strand, named ‘NcoI
replacing HindIII-OT’ were used to re-engineer the orientation
of the strand. Following the PCR, the entire AMR sequence
underwent a double digest with HindIII and NcoI. Upon
completion of the restriction digest, a Phenol/Chloroform

3

1

10

0.5

Confirmation

0.2

of AMR PCR
10

extraction was performed to purify the AMR product. Gel

product. The
expected
Figure 10

electrophoresis (See Figure 10) and was performed on the
10

AMR product to ensure size of the product. Once confirmed

Figure 2

band size is

Confirmation of AMR

356 base

PCR product. The

that the product was of desired size the process was repeated
on a larger scale and gel analysis had a concentration of 725

expected band size is
356 base pairs.

ng Restricted Flipped Insert used in the gel analysis (see
Figure 10). The NanoSpec reading on the total collected volume was 6640 ng total of
AMR insert from the PCR reaction.

6.3 Purification of Restricted pET11d Plasmid

Generation of new E.coli DH5α containing the pET11d plasmid was performed to
have ample stock for the pET11d-AMR ligation reaction. For the generation of sticky
ends, the pET11d vector was restricted with NcoI in the thermocycler for 3 hours at
37°C, followed by heat inactivation at 80°C for 20 minutes, and held at 4°C until removal
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from thermocycler. A 1% agarose gel containing Phenix Red was the standard for all gel
purifications with the bands excised under UV light, and plasmid DNA harvested via
QIAEX-II gel extraction kit (see Figure 11).
When using the gel extraction kit, following the
manufacturer's protocol except for the heat
recommendation, a heat setting of 65°C to 70°C was
Lane

5

7

8

4

found to be optimal for extraction of DNA from the
QIAEX-II beads. The NanoSpec then quantified the
NcoI_pET11d plasmid concentrations to ensure both
4
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3

quantity and quality.
pET11d_NcoI plasmid was then restricted with
4

HindIII for 2 hours in the thermocycler, heat inactivated
Figure 11 pET-11d Restriction. In

at 80°, and held at 4°C. The pET11d_NcoI_HindIII

lanes 4 and 5 the plasmid has been

plasmid was 4CIP treated at 37°C in the thermocycler for

digested with HindIII, lanes 7 and 8

1 hour. Purified pET11d_NcoI_HindIII_CIP was

have been digested with NcoI.

obtained by two phenol/chloroform extraction and single
ethanol precipitation. Quantification was performed
using the NanoSpec reading to generate the total 180.4
ng of DNA.

Based on the band size an
estimated concentration of 600 ng
per lane of DNA.
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6.4 Insertion and Transformation of AMR Insert

The importance of molar ratios comes into
account for ligation reactions to occur between
pET11d_NcoI_HindIII_CIP and AMR. The
ligation was performed overnight at a 1:3 vector
to insert ratio at 16°C in the thermocycler. At the
completion of ligation, a transformation was
setup using competent E.coli DH5α cells, a gift

Figure 12 Transformation of p_AMR into E.coli

from a former GA-PCOM pharmacy student,

DH5α. The colonies were identified and circled

Betty Ma. To the competent cells, 10 ng of

so that origin could be traced in detail before
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Miniprep was performed to send the plasmid
DNA for analysis.
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plasmid was pipetted into them, heat
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shocked at 42°C for 30 seconds, thus

0.5

allowing the DNA to be transformed
into the E. coli cells. The cell cultures
Figure 13 Gel Electrophoresis Image of double
digested Transformation Product. The Miniprep
harvested plasmid was double digested with NcoI and

were grown overnight at 37°C and
colonies were observed (See Figure

HindIII as confirmation before sending samples for

12). Selections were made from the

sequencing analysis. The double digest plasmid has

chosen colonies and inoculated into 5

an expected size of 5,348 base pairs. Quick-Load 2-

ml LB broth with 50 µg/mL ampicillin

Log DNA Ladder (New England BioLabs, Ipswich,
Massachusetts, Catalog # N0550S) was employed for
size analysis.

and grown overnight Midiprep was
performed the following day. To
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confirm the ligation and transformation a success a double digest with NcoI and HindIII
on the harvested P_AMR plasmid was performed with the restricted plasmid being
5,348 bp and the fragment 251 bp (See Figure 13). The harvested plasmids were sent
to Retrogen for sequencing from the T7 (See Appendix A). A positive colony, named
P1CB1, was chosen as the Gold Stock colony for all future P_AMR plasmids due to its
complete sequence.

6.5 Annealing and Purification of PN2-KPI
The PN2-KPI inhibitor was annealed by mixing in equal concentrations of oligo and
heating to 94°C for 2 minutes, followed by slowly cooling to room temperature. A small
amount was then used to run for analysis and quantification of product.

6.6 Harvest of P_AMR for use in Transformation
P_AMR was then harvested from E.coli to be used for a series of restrictions
before the ligation of the PN2. The first restriction was with EcoRI as previously
performed with HindIII, followed by gel purification, and QIAEX-II gel extraction.
NanoSpec quantification and gel verification was used to ensure full linearization before
proceeding to the restriction with HindIII. Next, was a restriction of P_AMR_EcoRI with
HindIII for 2 hours was performed in the thermocycler at 37°C, followed by heat
inactivation at 80°C for 20 minutes. The p_AMR_EcoRI_HindIII was then treated with
CIP for 1 hour at 37°C. To purify p_AMR_EcoRI_HindIII_CIP a
phenol/chloroform/isoamyl extraction followed by ethanol precipitation, to ensure purity
of the restricted DNA. A quantification gel was used to determine the concentration of
plasmid DNA after completion of purification.
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6.7 Ligation and Transformation of p-AMR with PN2-KPI

A ligation reaction was set up between
p_AMR_EcoRI_HindIII_CIP and PN2 insert at a
molar ratio of 1:3 and 1:6. This reaction was placed
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Figure 14 Image of Transformation
colony selection of p_AMRI plasmid in

10

3

E.coli DH5α. Isolated colonies were
selected for inoculation to grow culture for

1

sequence confirmation.

0.5

in the thermocycler overnight at 16°C
and used in a transformation into

0.2

Figure 15 Gel Confirmation of desired p_AMRI product.

competent E.coli DH5α cells. The

The plasmid was digested with XbaI. On the engineered

chosen colonies (See Figure 14) were

p_AMRI XbaI has 2 different restriction sites in the cloned

grown in 5 ml LB broth with 5 µg/mL

sequence, which ejected a fragment of 356 base pairs in

ampicillin overnight, and a miniprep

length. Quick-Load 2-Log DNA Ladder (New England
BioLabs, Ipswich, Massachusetts, Catalog # N0550S)

was used to harvest the plasmid DNA.
To ensure the confirmation of the P_AMRI product, a restriction with XbaI resulted in the
expected ejection of a 356 base pair fragment (See Figure 15). After restriction
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confirmation, the p_AMRI plasmid was sent to Retrogen for sequencing analysis (See
Appendix B).

54

7 Discussion

The goal of this study was
to design and generate a lipid
Anchored Molecular Ruler with
attached Inhibitor (AMRI) at a
fixed height to quantify the
optimum reactive height for
FIXa (see Figure 16). Having a
hypothesized reactive height is
between 50 to 100Å above the
membrane it is important to
create AMRI to fluid data and
understanding of Serine

Figure 16. Hypothesized Action of AMRI interaction with FIXa on
a phospholipid surface. Here it can be seen how the AMRI (figure on
left) gets the right height and the flexible linker allows the inhibitor
to fit in the reactive site of FIXa (structure on the left)

Proteases, specifically for this
study FIXa. This was carried out by creation, purification, and sequencing of an AMRI in
an expression vector.
Previous studies have demonstrated the use of a variable length peptide linker and a
membrane bound inhibitor. The understandings of previous FRET studies delivered
great insight into a topographical orientation of the enzymes. Using the FRET data
allowed for height estimation of FIXa on a phospholipid surface, but it could not
necessarily correlate with the optimal reactive height, nor elasticity of the active site of
the enzyme when exhibiting maximum pro-coagulant activity. This study focused on the
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generation of a lipid-tethered inhibitor for use as a molecular ruler of FIXa through a
successful engineering and multi-step cloning process.
The p-LAGC-EAK10 plasmid underwent a restriction digest with Restriction
endonucleases, HindIII and NcoI, to produce a DNA fragment containing the LAGC and
(EAAAK)11 coding sequences. Using the molecular biology program, SnapGene, PCR
primers were designed to mutagenize the ends, inserting HindIII and NcoI sites opposite
to their original design. This “flipped” the sequence and inserted it into the correct
reading frame with the Tag7 site, coding for methionine.
Standard cloning techniques were employed to sub-clone the fragment into an empty
Pet11d vector, harvested from E. coli DH5α. PN2-KPI oligonucleotides were designed
on SnapGene and generated by Integrated DNA Technologies. The PN2-KPI
oligonucleotides were ordered in forward and reverse reading frames and annealed to
create overhangs for alignment with their EcoRI and HindIII restriction sites. For
conformation of correct annealing the product was purified using gel electrophoresis; the
bands excised were roughly 187 base pairs size.
A digest of EcoRI and HindIII produced the sticky ends for insertion and ligation of
annealed oligonucleotides encoding the sequence for PN2-KPI, into the constructed
AMR plasmid. The DNA was purified via Gel Electrophoresis and excising the band with
a product size of 5754 base pairs. The DNA was for sequencing starting at the Tag 7
promoter to ensure that the final gene product is correct.
The sequencing data (see Appendix B) demonstrate the success of generating a
constructed AMRI sequence in a multi-step molecular cloning process. Successful
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insertion of 11 EA3K repeats will result in the PN2-KPI inhibitor having a raised height of
roughly 83 Å above the membrane surface. Ideally the height of 83 Å will prove ideal for
inhibition of FIXa as crystal structures and previous FRET data have indicated that
active site is between 61 – 89 Å (59, 60, 68).
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8 Future Studies
8.1 Protein expression and purification of AMRI
8.1.1 Expression of LAGC-(EAAAK)11-PN2 (AMRI)
The construction of LAGC-(EAAAK)11-PN2 in DH5ɑ vector described in Specific
Aim 1 would be expressed in E. coli BL21(DE3). Carbenicillin would be used, replacing
Ampicillin, since it would confer more stability with β-lactamases and resistance to
producing satellite colonies in this expression step (82). The plasmid would confirm
correct coding sequence and correct reading frame orientation if E. coli BL21(DE3)
produces colonies. The cells would then be lysed, as expressed proteins would be
anchored in E. coli periplasmic space, with a zwitterionic detergent and would remain in
detergent. Using the detergent would provide a suitable environment for the protein,
since typically its lipid bound.

8.1.2 Affinity Column Purification of LAGC-(EAAAK)11-PN2 (AMRI)
Crude Cell Lysate

Purification of LAGC-(EAAAK)11-PN2 Crude Cell Lysate would be performed by
Affinity Column Purification in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl. The Affinity
column would be generated using Affi-Gel generating an amide bond to Trypsin. The
desired amount of Affi-Gel would be transferred into a funnel to separate and drain the
supernatant. The gel would then be washed three times with gel bed volumes of cold 10
mM Sodium Acetate, pH 4.5. Gel is transferred to a flask and the cold Trypsin solution
is added at 0.5 ml per ml of gel, followed by one hour of gentle agitation at room
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temperature. Once completed the gel with trypsin would be transferred to a column and
washed with water until column runs clear at O.D.280. The column was chosen since
Trypsin would bind with PN2-KPI attached at the end of the folded protein. The column
would be developed using an Equilibration Buffer of 20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 0.1% Triton-X100 with a flow rate of approximately 1 mL per 2.5 minute. The cell
lysate would then be loaded at a rate of approximately 1 mL per 2.5 minute. The cell
lysate would then be eluted with 10 mM HCl, 500 mM KCl, 0.1% Triton-X100, pH 2 at a
rate of 1 ml/min and fractions collected. Elutions would then be neutralized by adding 20
µl of 1M Tris-HCl, pH 7.5, as collected. Elution fractions would then be analyzed at A280
and relevant fractions would be pooled. The column would be stored at 4℃ and in the
starting buffer that contains 0.2% Sodium Azide (Unpublished protocol K. Baker).

8.1.3 Re-lipidation of LAGC-(EAAAK)11-PN2 (AMRI)

For proper expression of AMRI, re-lipidation must occur on a phospholipid surface
such as a liposome, this protocol has been adapted from Smith and Morrissey 2004
(84). These liposomes would form as the detergent is removed from, creating a layer for
AMRI to effectively sit along with FIXa. Using the A280 readings for estimated protein
concentration it would place in a ratio of 300 nM protein with 2.6 µM Phosphatidylcholine
(PC) lipid. The mixture would then be dried under Argon gas followed by continued
drying under a vacuum. The protein solution still in the elution buffer would be added to
solubilize the lipids. Detergent would be removed by adding 50 mg wet SM-2 bio beads
to pool the lipid vesicles. As the liposomes are forming, detergent is being removed, and
the protein should re-lipidate into the liposome. After two separate 1.5-hour rocking
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events the liquid around the beads would be collected; with an additional 350 mg wet
SM-2 bio beads added after first rocking.

8.1.4 Gel Filtration Chromatography

Gel Filtration Chromatography would be employed using a 16 ml sepharose CL 2B
300 column at room temperature. The column would be equilibrated in a High Salt TBS,
composed of 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl with a running flow of 1 ml/min. The
replipidated protein samples would then be added to the column and allowed to settle in
column matrix. The High Salt TBS would then flow over the column at a rate of 1 ml/min
and collecting fractions. The fraction turbidity would be analyzed at A600 to determine a
lipid elution profile and proteins would be measured at A280. Then proteins would be
analyzed on 15% SDS-PAGE gels, followed by Silver staining using the Morrissey 1981
protocol (85). This step would confirm the proteins are fixating to the lipid membrane
and not generating protein null liposomes. Proteins that are not bound to the liposome
would elute early as they are small, and the lipids would elute in later fractions. If the
proteins bind with the lipid they would elute in the same fractions.

8.1.5 Anticipated Results

I anticipate the engineering of the protein was correct and would produce a valid
product. Expression of the protein should be accomplished because the DNA sequence
is in the correct reading frame inducible under the IPTG. Isolation of the protein would
be possible as well because of Trypsin and its affinity for binding.
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8.1.6 Potential Problems and Alternative Strategies

Potential problems may arise in the extraction method with the detergent. The
detergent is essential in lysing the cells and providing soluble protein environment.
Adjustments would be made at each step and evaluated, since this protocol was
adapted from the purification of BPTI. The previous protocol also lacked the larger rigid
and flexible linker regions, which could affect how the inhibitor folds and behaves.
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8.2 Determine ability of AMRI to inhibit FIXa
8.2.1 Protocol
To study reactive height of FIX, AMRI was incorporated into a liposome as described
in specific Aim 2. The liposomes would be constructed of 2 anionic phospholipids,
phosphatidylserine, and phosphatidylcholine (PS and PC). Their concentrations would
be at 10% PS and 90% PC and should be able to promote optimal binding. It has been
demonstrated with their ability to bind Vitamin K-dependent clotting factors, which
contain the N-terminal g-carboxyglutamic acid (Gla) domain (9, 86). Once the liposome
bound with AMRI is dried to a 96- well plate activated FIXa would be added. FIXa has
been previously activated by Russell’s Viper Venom and stored frozen until needed.
Chromogenic substrate would be added and monitored at 405 nm to determine the
amount of active enzyme that remain unbound by the inhibitor, modified from
Neuenschwander et al. 2006 and Yu et al. 2014 (56, 87). Rates would be plotted
against inhibitor concentration to determine the Ki for AMRI.

8.2.2 Anticipated Results
I anticipate that AMRI would inhibit FIXa at the height hypothesized of using the
(EAAAK)11 insert between the LAGC anchor and PN2-KPI.

8.2.3 Potential Problems and Alternative Strategies
A potential problem is the sequence of repeats may alter the binding ability of KPI to
block the catalytic triad, therefore, to test this ability a mixture of inhibitor and substrate
could be placed in solution. If no reaction or weak reaction, this would be conclusive
that AMRI is ineffective in a FIXa topography study. It is also possible the inhibitor could
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be raised to an ineffective height; if weak inhibition then alternative repeats of EAAAK
could be used to determine the optimal height of FIX. This would require multiple
cloning experiments to adjust the EAAAK sequence repeats. Also, an issue that may
been encountered is either FIX or inhibitor does not anchor to the phospholipid for
correct positioning. If this is the case, then alternative concentration ratios of PS:PC
could be used to see if a different concentration as a greater anchoring affect.
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9 Clinical Significance

An abnormal blood clot forms in the blood vessel, called a thrombus. This thrombus
is the result of a clinical abnormality causing activation of the clotting cascade. If the
resulting thrombus moves in the vasculature, it is termed an embolus. An embolus
becomes dangerous as it travels and lodges in the narrowing of the vessel, restricting or
terminating blood flow.
Current medical treatment for a patient receiving a stent or angioplasty involves
multiple preparation steps to ensure the patient does not develop an embolus. The
current medical intervention relies heavily on drugs that interfere with the clotting
cascade. Patients going in for stent placement are given a Ca2+ channel antagonist and
injections of heparin during the procedure. Once the procedure is completed the use of
heparin and coumarin (i.e. Warfarin) are continued for 72 hours. Following the 72 hours
treatment with the coumarin is done for an indefinite amount of time, depending on the
patients clotting times (88) .
The hope of this study of pro-coagulant enzyme/membrane topography is to bridge
the knowledge gap by studying the distances of fully pro-coagulant enzyme complexes.
The information from this membrane-bound activity study could lead to the generation of
inhibitors with an increased specificity. Not only targeting enzyme reactivity but one
directed to specific membrane topography of each enzyme. Therefore, the results of a
study with AMRI could greatly impact clinical therapies aimed at coagulation reaction
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inhibition. Most importantly of the therapies impacted the most would be treatment of
thrombosis, surgical procedures, and the implantation of medical devices (i.e. stents)
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